Our latest Q and A for premium subscribers is with Pedro Gonzalez de Cosia, the CEO of Pharmakon, the manager of BioPharma Credit,  a specialist loan provider to life sciences companies. The trust has recently announced it is moving from the specialist segment to the main  market in London. The trust is managed out of New York and was launched in March 2017, so is coming up shortly to its fifth anniversary. Given its 7.2% yield, it has been on my radar for a few weeks now as a candidate for the income portfolio (and my SIPP).

The Q and A recording is here.

In my own portfolios I have until r...